26 research outputs found

    ์˜ค์กด, ์˜ค์กด๊ณผ์‚ฐํ™”์ˆ˜์†Œ์™€ ์˜ค์กดํ™œ์„ฑํƒ„ ์ฒ˜๋ฆฌ์— ์˜ํ•œ ํŽ˜๋†€ ๋ฐ ๊ทธ ๋ถ€์‚ฐ๋ฌผ์˜ ์ œ๊ฑฐ์— ๊ด€ํ•œ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธๅคงๅญธๆ ก ไฟๅฅๅคงๅญธ้™ข :็’ฐๅขƒไฟๅฅๅญธ็ง‘ ็’ฐๅขƒ่ก›็”Ÿๅญธๅฐˆๆ”ป,1997.Maste

    Atypical Presentation of Pneumocystis jirovecii Infection in HIV Infected Patients: Three Different Manifestations

    No full text
    Advances in the treatment and prevention of Pneumocystis jirovecii infection (PJI) in human immunodeficiency virus (HIV) patients decreased incidence and mortality dramatically, however, it may be associated with an increased frequency of unusual manifestation such as cystic formation, pneumothorax, focal infiltration, nodular formation, or extrapulmonary lesions. We report three cases of PJI with atypical manifestations. Each case demonstrates different clinical features: multiple nodular pulmonary lesion (32-year-old man with abnormal chest X-ray finding), subpleural mass-like lesion (43-year-old man with left visual loss and right pleuritic chest pain), and extrapulmonary mass-like lesions in the liver, lymph nodes, and small bowel (39-year-old man with cough, sputum, and dyspnea). P. jirovecii was confirmed in all 3 cases and they were treated well. It is necessary to understand that PJI shows variable clinical features

    Predictors of mortality in Middle East respiratory syndrome (MERS)

    No full text
    We evaluated the clinical characteristics, cytokine/chemokine concentrations, viral shedding and antibody kinetics in 30 patients with Middle East respiratory syndrome (MERS), including 6 non-survivors admitted to 3 MERS-designated hospitals. Old age, low albumin, altered mentality and high pneumonia severity index score at admission were risk factors for mortality. In addition, severe signs of inflammation at initial presentation (at hospital days 1-4), such as high inducible protein-10 (p=0.0013), monocyte chemoattractant protein-1 (p=0.0007) and interleukin 6 (p=0.0007) concentrations, and poor viral control (high viral load at hospital days 5-10, p<0.001) without adequate antibody titres (low antibody titre at hospital days 11-16, p=0.07) during the course of disease, were associated with mortality.This study was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2774, HI15C2859 and HI15C2888), from the National Research Foundation, funded by the Ministry of Science, ICT and Future Planning, Republic of Korea (NRF-2015R1A4A1042416), and from the Asan Institute for Life Sciences (Grant No. 2016-462). It was also supported by the Korean Society for Chemotherapy

    Development of Heavy Metal Resistant Plants by Expression of ZntA from E. coli

    No full text
    Maste

    ์œ„์•” ์„ธํฌ์ฃผ์—์„œ CDK4/6 inhibitor์˜ ๊ฐ์ˆ˜์„ฑ ํ‰๊ฐ€์™€ biomarker ํƒ์ƒ‰

    No full text
    Gastric cancer (GC) is the fourth most common cancer and second leading cause of cancer mortality worldwide. The median survival of patients with metastatic gastric cancer has a poor prognosis, less than 2 years. Recent development of molecular biological research suggests trastuzumab and ramucirumab as targeted therapies for GC. However, there are limitations that only 10% of GC patients are HER2-positive for trastuzumab therapy, and that identified ramucirumab biomarker is scarce emphasizing the need to find novel targeted agents to improve outcomes. Recently, therapeutics targeting CDK that regulate the cell cycle have been developed and clinical trials are undergoing in various cancers, especially those investigating the G1 phase arrest induced by CDK4 and CDK6 inhibitions. CDK4/6 inhibitors have demonstrated tumor growth suppression in several PDX models, including non-small cell lung cancer (NSCLC), melanoma, and glioblastoma; however, their efficacy in gastric cancer is not sufficiently supported. In this study, we investigated the anti-proliferative effect of abemaciclib in gastric cancer and conducted the search for a biomarker that can predict its response. We profiled G1/S related genetic and molecular characteristics in 49 gastric cancer cell lines and pinpointed the factors associated with abemaciclib sensitivity with augmented focus on the methylation of p16 gene. p16 methylation was the most prominent predictive marker of abemaciclib sensitivity, and change in abemaciclib response was observed when a decrease in methylation levels was induced. The anti-proliferative effect of abemaciclib, which induces G1 phase arrest and inhibits Rb phosphorylation, was confirmed in vitro and in vivo. Hence, we propose CDK4/6 inhibitors as promising targeted agents and the methylation of p16 as a predictive marker in gastric cancer. ์œ„์•”์€ ์ „์„ธ๊ณ„์ ์œผ๋กœ ๋„ค๋ฒˆ์งธ๋กœ ๋†’์€ ๋ฐœ๋ณ‘๋ฅ ์„ ๋‚˜ํƒ€๋‚ด๋ฉฐ ์•” ์‚ฌ๋ง์›์ธ 3์œ„์ด๋‹ค. ์ „์ด์„ฑ ์œ„์•”ํ™˜์ž์˜ ์ค‘์•™ ์ƒ์กด๊ธฐ๊ฐ„์€ 2๋…„ ๋ฏธ๋งŒ์œผ๋กœ ์ข‹์ง€ ์•Š์€ ์˜ˆํ›„๋ฅผ ๋ณด์ธ๋‹ค. ์ตœ๊ทผ ๋ถ„์ž ์ƒ๋ฌผํ•™์ ์ธ ์—ฐ๊ตฌ์™€ ๊ธฐ์ˆ ์˜ ๊ฐœ๋ฐœ๋กœ ๋งž์ถค์น˜๋ฃŒ์˜ ์ผํ™˜์œผ๋กœ HER2 ์–‘์„ฑ์ธ ์ง„ํ–‰์„ฑ ์œ„์•”ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ HER2์— ๋Œ€ํ•œ ๋‹จ์ผํด๋ก  ํ•ญ์ฒด์ธ trastuzumab์˜ ์‚ฌ์šฉ๊ณผ 2์ฐจ ์น˜๋ฃŒ ์ „๋žต์œผ๋กœ์จ ramucirumab์ด ์น˜๋ฃŒ ์˜ต์…˜์œผ๋กœ ๊ถŒ๊ณ ๋œ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ HER2 ์–‘์„ฑ ์œ„์•” ํ™˜์ž๋Š” 10%์— ๋ถˆ๊ณผํ•˜๋ฉฐ ์ž…์ฆ๋œ ramucirumab์˜ biomarker๋Š” ์—†๋‹ค. ๋”ฐ๋ผ์„œ ์˜ˆํ›„๊ฐ€ ์ข‹์ง€ ์•Š๊ณ  ์œ ๋ณ‘๋ฅ ์ด ๋†’์€ ์ง„ํ–‰์„ฑ ์œ„์•” ์น˜๋ฃŒ์— ๋Œ€ํ•œ ์ƒˆ๋กœ์šด ์ ‘๊ทผ ๊ธฐ๋ฒ•์ด ์ ˆ์‹คํ•œ ์ƒํ™ฉ์ด๋‹ค. ์ตœ๊ทผ ์„ธํฌ์ฃผ๊ธฐ๋ฅผ ์กฐ์ ˆํ•˜๋Š” CDK๋ฅผ ํ‘œ์ ์œผ๋กœ ํ•˜๋Š” ์น˜๋ฃŒ์ œ๋“ค์ด ๊ฐœ๋ฐœ๋˜๊ณ  ๋‹ค์–‘ํ•œ ์•” ์ข…์—์„œ ์ž„์ƒ์‹œํ—˜์ด ์ง„ํ–‰ ์ค‘์ด๋‹ค. ๊ทธ ์ค‘ CDK4์™€ CDK6๋ฅผ ์ด์ค‘์œผ๋กœ ์–ต์ œํ•˜์—ฌ G1๊ธฐ์˜ arrest๋ฅผ ์œ ๋„ํ•˜๋Š” ์–ต์ œ์ œ๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ๋งŽ์€ ์ž„์ƒ ์—ฐ๊ตฌ๊ฐ€ ์ง„ํ–‰ ์ค‘์ด๊ณ  ๋Œ€ํ‘œ์ ์œผ๋กœ palbociclib (Pfizer), abemaciclib (Lilly), ribociclib (Novartis) ๋“ฑ์ด ์žˆ๋‹ค. CDK4/6 inhibitor๋Š” ๋น„์†Œ์„ธํฌํ์•” (NSCLC), ํ‘์ƒ‰์ข…, ์•„๊ต๋ชจ์„ธํฌ์ข…์„ ๋น„๋กฏํ•œ ์—ฌ๋Ÿฌ PDX ๋ชจ๋ธ์—์„œ ์ข…์–‘ ์„ฑ์žฅ ์–ต์ œ ํšจ๊ณผ๋ฅผ ๋‚˜ํƒ€๋ƒˆ๊ณ  ์œ ๋ฐฉ์•”, ํ‘์ƒ‰์ข…์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์ž„์ƒ 1์ƒ ์‹œํ—˜์—์„œ ํšจ๊ณผ๋ฅผ ๋ณด์˜€์ง€๋งŒ ์œ„์•”์—์„œ CDK4/6 inhibitor๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์—ฐ๊ตฌ๋Š” ์ ์€ ์ƒํ™ฉ์ด๋‹ค. ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ์œ„์•”์—์„œ CDK4/6 inhibitor์ธ abemaciclib์˜ ํ‘œ์ ์น˜๋ฃŒ์ œ๋กœ์จ์˜ ํšจ๊ณผ๋ฅผ ํ™•์ธํ•˜๊ณ , ์•ฝ์ œ์˜ ํšจ๊ณผ๋ฅผ ์˜ˆ์ธกํ•  ์ˆ˜ ์žˆ๋Š” biomarker๋ฅผ ์ฐพ์•„๋ณด๊ณ ์ž ํ•œ๋‹ค. 49๊ฐœ ์œ„์•”์„ธํฌ์ฃผ์—์„œ G1/S๊ธฐ ๊ด€๋ จ ์ธ์ž์˜ ์œ ์ „์  ๋ณ€์ด์™€ ๋ฐœํ˜„์„ ํ™•์ธํ•˜๊ณ  abemaciclib ๊ฐ์ˆ˜์„ฑ๊ณผ ๊ด€๋ จ ์ง€์–ด ํšจ๊ณผ๋ฅผ ๋‚˜ํƒ€๋‚ด๋Š” ์ธ์ž๋ฅผ ์ฐพ์•„๋ณธ ๊ฒฐ๊ณผ p16 ์œ ์ „์ž์˜ methylation์ด abemaciclib ๊ฐ์ˆ˜์„ฑ๊ณผ ์—ฐ๊ด€์ด ์žˆ๋Š” ๊ฒƒ์„ ํ™•์ธํ•˜์˜€๊ณ  ์ด๋ฅผ ์ฆ๋ช…ํ•˜๊ธฐ ์œ„ํ•ด methylation ์ˆ˜์ค€์„ ๊ฐ์†Œ์‹œ์ผฐ์„ ๋•Œ์˜ abemaciclib ๊ฐ์ˆ˜์„ฑ ๋ณ€ํ™”๋ฅผ ํ™•์ธํ–ˆ๋‹ค. ๋˜ํ•œ abemaciclib ๊ฐ์ˆ˜์„ฑ์„ ํ† ๋Œ€๋กœ ์„ธํฌ์ฃผ๋ฅผ ์„ ๋ณ„ํ•œ ๋’ค, ์•ฝ์ œ์˜ ํšจ๋Šฅ์„ in vitro์™€ in vivo ์ƒ์—์„œ ํ™•์ธํ•˜์˜€๋‹ค. ์ด๋กœ์จ CDK4/6 ์–ต์ œ์ œ๊ฐ€ ์œ„์•” ์น˜๋ฃŒ์— ์žˆ์–ด ์œ ๋งํ•˜๋ฉฐ p16์˜ methylation์€ ์•ฝ์ œ์˜ ํšจ๊ณผ๋ฅผ ์˜ˆ์ธกํ•  ์ˆ˜ ์žˆ๋Š” predictive marker๋กœ ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ์Œ์„ ์ œ์‹œํ•˜๊ณ ์ž ํ•œ๋‹ค.open์„

    ๊ธฐ์—…์˜ ์žฌ๋ฌด์ œ์•ฝ.ํˆฌ์ž.ํ˜„๊ธˆ๋ณด์œ ์— ๊ด€ํ•œ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ) --์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ฒฝ์˜ํ•™๊ณผ(์žฌ๋ฌด๊ธˆ์œต์ „๊ณต),2010.8.Maste

    Sequence analysis and expression of the gene encoding the 56-kilodalton protein of Rickettsia tsutsugamushi TA686

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์˜ํ•™๊ณผ ๋ฏธ์ƒ๋ฌผํ•™์ „๊ณต,1996.Docto
    corecore